

# Over 1000 Biologics Under Development Will Drive The Biologics Market To 10% Yearly Growth

LONDON, GREATER LONDON, UK, June 8, 2018 /EINPresswire.com/ -- The growth rate in the market for biologics has accelerated from the 5.4% it was achieving up to 2017 to a forecast 9.6% to 2021, [a report from The Business Research Company shows](#). A significant driver of this growth will be the over 1000 new biologics currently under development, leading to an expected multiplication of the 2017 approval rate of 12 biologics in the USA, 10 in the European Union and 7 in Japan. The global market for biologics is now almost a quarter as big as that for pharmaceutical drugs and it accounts for 3% of global healthcare expenditure.

Biologics are very large complex molecules manufactured in living systems such as microorganisms, animal cells or plant cells. They are produced using recombinant DNA technology and are composed of sugars, proteins, nucleic acids or a combination of these substances.

Oncology is the largest therapeutic area segment for biologics, worth about 50% of the entire market. The cardiovascular and cerebrovascular therapeutic area is a much smaller segment, despite the great and increasing importance of these diseases; in this young market this is partly due to supply-side factors such as the rate of discovery.

North America's biologics market is the largest, worth nearly 40% of the total, followed by Western Europe at 23% and Asia Pacific at 16%. By country, the market in the USA dominates, being worth \$61.1 billion, nearly seven times as much as the second-largest, Japan. The largest single segment is the US market for monoclonal antibodies, which is worth \$27.1 billion.

The biologics market is quite concentrated: the top five competitors' shares amounted to 59% of the total in 2017. Johnson & Johnson, Hoffman-La Roche and Bristol-Myers Squibb are the three largest players.

## Where to Learn More


Read the [Biologics Market Report](#) from [The Business Research Company](#) for information on the following:

Markets Covered: Biologics, Monoclonal Antibodies, Therapeutic Proteins and Vaccines

Biologics Companies Mentioned: Amgen, AbbVie, Johnson & Johnson, Bristol-Meyers Squib, Pfizer, Eli Lilly and Company, F. Hoffmann-La Roche, Merck & Co., GlaxoSmithKline, Sanofi

Countries: India, China, Japan, Australia, UK, Germany, France, Italy, Spain, Russia, USA, Brazil

Regions: North America, South America, Western Europe, Eastern Europe, Africa, Middle East, Asia



Pacific

Time Series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, population, GDP, Biologics Indicators Comparison.

Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report are sourced using endnotes.

Oliver Guirdham

The Business Research Company

+44 207 1930 708

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.